Comparing the current results to its competitors, Biodesix Inc reported Revenue increase in the 2 quarter 2026 by 34.18 % year on year. The sales growth was above Biodesix Inc 's competitors' average revenue growth of 25.34 %, achieved in the same quarter.
Biodesix Inc 's Comment on Competition and Industry Peers
The company operates in the diagnostic testing market for lung cancer, offering a portfolio that includes tests for diagnosis, treatment, and monitoring. Its Nodify XL2 and Nodify CDT tests face competition from Veracyte, Inc. The VeriStrat immune profiling test currently has no known competitors. The company's genomic tests, GeneStrat ddPCR and GeneStrat NGS, compete with academic hospital laboratories and companies such as Guardant Health and Foundation Medicine. In tumor profiling, key competitors include Guardant Health, Foundation Medicine, Tempus AI, and NeoGenomics. In immune profiling, the primary competitors are Adaptive Biotechnologies and Personalis. The company operates a CLIA-certified laboratory in Louisville, Colorado, utilizing proprietary semi-automated workflows to deliver tests efficiently.
May 22, 2025
At the 2025 ASCO Annual Meeting, Biodesix announced significant discoveries from their INSIGHT study, emphasizing the predictive capabilities of the VeriStrat Host Immune Classifier (HIC) in assessing overall survival outcomes for patients with non-small cell lung cancer (NSCLC) treated with immunotherapies. This article provides a overview of the study s findings and their implications on clinical practices.Non-small cell lung cancer (NSCLC) remains one of the most prevalent and challenging cancers to treat worldwide. Recent innovations have enabled more personalized approaches to therapy, with biotechnological advances offering promise for improved outcomes. At the forefront of these innovations is Biodes...
May 9, 2024
Biodesix Announces Impressive First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule ManagementLOUISVILLE, Colo. - Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company specializing in lung disease, has reported its financial and operating results for the first quarter ended March 31, 2024. The company s performance during this period showcased remarkable revenue and volume growth, along with a significant improvement in gross margins. Biodesix s CEO, Scott Hutton, expressed his satisfaction with the results and highlighted the company s commitment to execution.According to the Q1 2024 report, Biodesix achieved over 50% revenue and volume growth, affirming its ...
Thryv Holdings Inc operates as a software-as-a-service (SaaS) company, offering a comprehensive suite of business management solutions to small and medium-sized businesses. Their business model relies on providing these software tools, including customer relationship management, marketing automation, and payment processing, to help businesses streamline their operations and enhance their efficiency.
Personalis Inc's business model revolves around offering advanced genomic sequencing and data analysis solutions to empower researchers and healthcare providers in their efforts to develop precision medicine and personalized therapies.
Pmv Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing precision therapies for cancer patients. They employ a collaborative business model that combines deep scientific expertise, strategic partnerships, and advanced technology to identify and target specific genetic alterations in cancer cells. By leveraging these insights, Pmv Pharmaceuticals aims to create innovative treatments that can improve patient outcomes and address unmet medical needs in oncology.
Natera Inc operates as a genetic testing company that provides non-invasive screening and diagnostic tests for reproductive health, oncology, and organ transplantation. The company's business model is built around offering cost-effective and accurate genetic testing solutions for both patients and healthcare providers. Natera primarily generates revenue by selling its proprietary tests and associated analysis services to customers, including hospitals, laboratories, and physicians.
Sources:
Biodesix Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biodesix Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
